Literature DB >> 14551506

Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution.

Georg Lenz1, Ulrich T Hacker, Wolfgang Kern, Andreas Schalhorn, Wolfgang Hiddemann.   

Abstract

We reviewed the records of 25 colon cancer patients consecutively treated with an oxaliplatin-containing regimen. We differentiated between hypersensitivity reactions and pain reactions due to oxaliplatin. The patients did not receive preventive pre-medication. Four patients underwent an adverse reaction. Three patients fulfilled the criteria of a hypersensitivity reaction with tachycardia, chills and hyperhidrosis. In addition, two patients suffered from severe abdominal and chest pain. Reactions occurred during or shortly after the oxaliplatin infusion. All patients recovered under symptomatic therapy. After reacting for the first time, pre-medication was applied prior to the oxaliplatin infusion. However, due to further reactions, the treatment protocol had to be changed in all cases into a regimen not containing oxaliplatin. We conclude that adverse reactions are relatively frequent toxic side-effects of oxaliplatin, mainly in heavily pre-treated patients. Pre-medication was ineffective in preventing further reactions and consequently the treatment regimen had to be changed in all cases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551506     DOI: 10.1097/00001813-200310000-00007

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

Review 1.  Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication.

Authors:  Ming-Yang Lee; Muh-Hwa Yang; Jin-Hwang Liu; Chueh-Chuan Yen; Pang-Chan Lin; Hao-Wei Teng; Wei-Shu Wang; Tzeon-Jye Chiou; Po-Min Chen
Journal:  Support Care Cancer       Date:  2006-07-25       Impact factor: 3.603

2.  High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.

Authors:  Yasuhiro Kidera; Taroh Satoh; Shinya Ueda; Wataru Okamoto; Isamu Okamoto; Soichi Fumita; Kimio Yonesaka; Hidetoshi Hayashi; Chihiro Makimura; Kunio Okamoto; Hidemi Kiyota; Junji Tsurutani; Masaki Miyazaki; Masahiro Yoshinaga; Kimiko Fujiwara; Yuzuru Yamazoe; Kenzo Moriyama; Masanobu Tsubaki; Yasutaka Chiba; Shozo Nishida; Kazuhiko Nakagawa
Journal:  Int J Clin Oncol       Date:  2011-01-18       Impact factor: 3.402

3.  Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.

Authors:  Qiuyan Song; Yuanxuan Cai; Kangyuan Guo; Min Li; Zaoqin Yu; Qirui Tai; Yuhang Zhao; Xuan Zhu; Chengliang Zhang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

4.  Cancer-induced expansion and activation of CD11b+ Gr-1+ cells predispose mice to adenoviral-triggered anaphylactoid-type reactions.

Authors:  Kalyan Pande; Roanna Ueda; Todd Machemer; Manjiri Sathe; Van Tsai; Elena Brin; Matthew J Delano; Nico Van Rooijen; Terrill K McClanahan; James E Talmadge; Lyle L Moldawer; Joseph H Phillips; Drake M LaFace
Journal:  Mol Ther       Date:  2009-01-06       Impact factor: 11.454

Review 5.  Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis.

Authors:  Jui-Ho Wang; Tai-Ming King; Min-Chi Chang; Chao-Wen Hsu
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

6.  The impact of different chelating leaving groups on the substitution kinetics of mononuclear Pt(II)(1,2-trans-R,R-diaminocyclohexane)(X-Y) complexes.

Authors:  Nadine Summa; Tanja Soldatović; Lutz Dahlenburg; Zivadin D Bugarcić; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2007-01-24       Impact factor: 3.862

Review 7.  Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients.

Authors:  Linhui Zhu; Huan Li; Qiong Du; Xuan Ye; Sijia Yu; Xin Luo; Qing Zhai
Journal:  Int J Clin Oncol       Date:  2021-10-09       Impact factor: 3.402

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.